State of New Jersey Common Pension Fund D Trims Stake in CRISPR Therapeutics AG $CRSP

State of New Jersey Common Pension Fund D lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 19.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 40,270 shares of the company’s stock after selling 9,915 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CRISPR Therapeutics were worth $2,610,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Atlantic Union Bankshares Corp acquired a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at $33,000. Thompson Investment Management Inc. acquired a new stake in CRISPR Therapeutics during the third quarter valued at $33,000. Strategic Wealth Investment Group LLC purchased a new position in CRISPR Therapeutics in the second quarter valued at $36,000. Bogart Wealth LLC raised its position in shares of CRISPR Therapeutics by 333.3% in the third quarter. Bogart Wealth LLC now owns 650 shares of the company’s stock worth $42,000 after acquiring an additional 500 shares during the period. Finally, Covestor Ltd purchased a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $48,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 2,112 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $111,048.96. Following the transaction, the general counsel owned 85,115 shares of the company’s stock, valued at $4,475,346.70. This represents a 2.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the sale, the chief executive officer directly owned 134,201 shares of the company’s stock, valued at $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 99,079 shares of company stock worth $5,643,674 over the last quarter. 4.30% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Down 2.2%

Shares of NASDAQ:CRSP opened at $53.46 on Friday. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $78.48. The stock has a market cap of $5.13 billion, a P/E ratio of -8.20 and a beta of 1.72. The business has a fifty day moving average of $53.84 and a two-hundred day moving average of $57.24.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The firm had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company’s revenue for the quarter was down 97.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.01) EPS. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Pipeline and earnings reaction — MarketBeat notes investors cheered Q4 results for pipeline progress and CASGEVY adoption (cash runway ~ $1.9B, CTX611 upside). That optimism helped the stock rebound after earnings even though reported revenue was small due to revenue-sharing with Vertex. CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
• Positive Sentiment: Bull case on long-term upside — Seeking Alpha highlights a “Buy” thesis driven by CASGEVY launch economics and CTX611 potential (modeled high peak sales), arguing significant upside exists despite high risk. Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
• Neutral Sentiment: Short-interest data ambiguous — reported short interest entries show zero shares/NaN changes and a 0.0 days ratio, which appears to be a reporting artifact rather than meaningful positioning information. No clear short-squeeze or build-up signal.
• Neutral Sentiment: Reassessment pieces — coverage (Yahoo) asks whether the recent rebound warrants a rethink, reflecting mixed analyst views and technical levels to watch; useful for investors weighing timing. Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Share Price Rebound?
• Negative Sentiment: Insider selling — CEO Samarth Kulkarni and General Counsel James Kasinger sold shares on Feb 19 (CEO ~6,967 shares; GC ~2,112 shares), modestly reducing their positions. Insider sales can signal near-term caution to some investors. CEO Filing GC Filing
• Negative Sentiment: Near-term fundamentals and skepticism — Q4 showed a big EPS miss and revenue limited by a revenue-share with Vertex; some analysts (e.g., Morgan Stanley cited in coverage) remain cautious with low price targets. Pessimistic takes (Fool) question the long-term payoff versus risk. Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Wall Street Analyst Weigh In

CRSP has been the topic of a number of analyst reports. Citigroup restated a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th. Wedbush dropped their price objective on CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a report on Wednesday, November 5th. Evercore reaffirmed an “outperform” rating and set a $74.00 target price on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Finally, Morgan Stanley reissued an “underweight” rating and issued a $33.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $64.24.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.